3 completed, 3 terminated, 2 unknown, 1 suspended. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Terminated 3, Unknown 2, Suspended 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Physiological Effects of Drugs: new trials by email Literature Review of Physiological Effects of Drugs trials Research Report on Physiological Effects of Drugs
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 89 | 2021-09-08 | 2024-03-19 |
| Relative Bioavailability of LY03010 Compared to Listed Drug LY03010; paliperidone palmitate, INVEGA SUSTENNA - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 281 | 2021-01-13 | 2023-04-25 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | Celularity Incorporated | 3 | 2020-10-01 | 2022-08-10 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | Celularity Incorporated | 29 | 2020-05-12 | 2023-02-16 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production empagliflozin (Jardiance) 25 mg - Empaglifozin, Physiological Effects of Drugs | Phase 1 | Completed | National Institute on Aging (NIA) | 21 | 2019-03-28 | 2022-08-02 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies SHR-1603 - Physiological Effects of Drugs, Neoplasms by Histologic Type | Phase 1 | Suspended | Jiangsu HengRui Medicine Co., Ltd. | 128 | 2018-11-13 | 2021-03-22 |
| Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine Vaccinations on Day 0, Day 28, and Day 140 - Encephalitis, Encephalitis, Viral | Phase 1 | Unknown | SRI International | 48 | 2018-07-17 | 2021-02-23 |
Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Immune System Diseases (2) · Mental Disorders (2) · Mood Disorders (2) · Neoplasm, Residual (2) · Neoplasms (2) · Psychotic Disorders (2) · RNA Virus Infections (2) · Schizophrenia (2) · Virus Diseases (2) · Alphavirus Infections (1) · Alzheimer Disease (1) · Blood Protein Disorders (1)
Hemic and Lymphatic Diseases (3) · Infections (2) · Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Acid-Base Imbalance (1) · Acidosis (1) · Arbovirus Infections (1) · Astrocytoma (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1)
Paliperidone Palmitate (2) · empagliflozin (1)
Celularity Incorporated (4) · Luye Pharma Group Ltd. (2) · Jiangsu HengRui Medicine Co., Ltd. (1) · National Institute on Aging (NIA) (1) · SRI International (1)
United States (8) · China (1)
Rui Li, MD (2) · Adrian Kilcoyne, MD (1) · Corey Casper, MD MPH (1) · Josephine M Egan, M.D. (1) · Sascha Goonewardena, MD (1) · Sharmila Koppisetti, M.D (1) · Sharmila Koppisetti, MD (1)